Allogeneic stem cell (SC)-based therapy is a promising tool for the treatment of a range of human degenerative and inflammatory diseases. Many reports highlighted the immune modulatory properties of some SC types, such as mesenchymal stromal cells (MSCs), but a comparative study with SCs of different origin, to assess whether immune regulation is a general SC property, is still lacking. To this aim, we applied highly standardized methods employed for MSC characterization to compare the immunological properties of bone marrow-MSCs, olfactory ectomesenchymal SCs, leptomeningeal SCs, and three different c-Kit-positive SC types, that is, amniotic fluid SCs, cardiac SCs, and lung SCs. We found that all the analyzed human SCs share a common pattern of immunological features, in terms of expression of activation markers ICAM-1, VCAM-1, HLA-ABC, and HLA-DR, modulatory activity toward purified T, B, and NK cells, lower immunogenicity of inflammatory-primed SCs as compared to resting SCs, and indoleamine-2,3-dioxygenase-activation as molecular inhibitory pathways, with some SC type-related peculiarities. Moreover, the SC types analyzed exert an anti-apoptotic effect toward not-activated immune effector cells (IECs). In addition, we found that the inhibitory behavior is not a constitutive property of SCs, but is acquired as a consequence of IEC activation, as previously described for MSCs. Thus, immune regulation is a general property of SCs and the characterization of this phenomenon may be useful for a proper therapeutic use of SCs.
DelaRosaO, LombardoE. 2010. Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. Mediators Inflamm, 2010:865601.
3.
Gonzalez-ReyE, AndersonP, GonzalezMA, RicoL, BuscherD, DelgadoM. 2009. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut, 58:929–939.
4.
Le BlancK, FrassoniF, BallL, LocatelliF, RoelofsH, LewisI, LaninoE, SundbergB, BernardoME, RembergerM, DiniG, EgelerRM, BacigalupoA, FibbeW, RingdenO. Developmental Committee of the European Group for Blood and Marrow Transplantation. 2008. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371:1579–1586.
5.
Le BlancK, RasmussonI, SundbergB, GotherstromC, HassanM, UzunelM, RingdenO. 2004. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363:1439–1441.
6.
PolchertD, SobinskyJ, DouglasG, KiddM, MoadsiriA, ReinaE, GenrichK, MehrotraS, SettyS, SmithB, BartholomewA. 2008. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol, 38:1745–1755.
7.
YañezR, LamanaML, García-CastroJ, ColmeneroI, RamírezM, BuerenJA. 2006. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells, 24:2582–2591.
KramperaM, PasiniA, PizzoloG, CosmiL, RomagnaniS, AnnunziatoF. 2006. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol, 6:435–441.
14.
UccelliA, MorettaL, PistoiaV. 2008. Mesenchymal stem cells in health and disease. Nat Rev Immunol, 8:726–736.
15.
FiorinaP, JurewiczM, AugelloA, VerganiA, DadaS, La RosaS, SeligM, GodwinJ, LawKet al.2009. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol, 183:993–1004.
16.
GonzalezMA, Gonzalez-ReyE, RicoL, BuscherD, DelgadoM. 2009. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum, 60:1006–1019.
17.
RafeiM, BirmanE, FornerK, GalipeauJ. 2009. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther, 17:1799–1803.
UccelliA, MancardiG, ChiesaS. 2008. Is there a role for mesenchymal stem cells in autoimmune diseases?Autoimmunity, 41:592–595.
20.
ZhangQ, ShiS, LiuY, UyanneJ, ShiY, LeAD. 2009. Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol, 183:7787–7798.
21.
Di NicolaM, Carlo-StellaC, MagniM, MilanesiM, LongoniPD, MatteucciP, GrisantiS, GianniAM. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99:3838–3843.
22.
KramperaM, CosmiL, AngeliR, PasiniA, LiottaF, AndreiniA, SantarlasciV, MazzinghiB, PizzoloGet al.2006. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24:386–398.
23.
KramperaM, GlennieS, DysonJ, ScottD, LaylorR, SimpsonE, DazziF. 2003. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 101:3722–3729.
24.
Le BlancK, TammikL, SundbergB, HaynesworthSE, RingdenO. 2003. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol, 57:11–20.
25.
MenardC, PacelliL, BassiG, DulongJ, BifariF, BezierI, ZanoncelloJ, RicciardiM, LatourMet al.2013. Clinical-grade mesenchymal stromal cells produced under various GMP processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev, 22:1789–1801.
26.
PrigioneI, BenvenutoF, BoccaP, BattistiniL, UccelliA, PistoiaV. 2009. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells, 27:693–702.
27.
SpaggiariGM, CapobiancoA, BecchettiS, MingariMC, MorettaL. 2006. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 107:1484–1490.
28.
KramperaM, SartorisS, LiottaF, PasiniA, AngeliR, CosmiL, AndreiniA, MosnaF, BonettiBet al.2007. Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. Stem Cells Dev, 16:797–810.
29.
MoorefieldEC, McKeeEE, SolchagaL, OrlandoG, YooJJ, WalkerS, FurthME, BishopCE. 2011. Cloned, CD117 selected human amniotic fluid stem cells are capable of modulating the immune response. PLoS One, 6:e26535.
30.
NajarM, RaicevicG, BoufkerHI, Fayyad-KazanH, De BruynC, MeulemanN, BronD, ToungouzM, LagneauxL. 2010. Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A, 16:3537–3546.
31.
RenG, ZhangL, ZhaoX, XuG, ZhangY, RobertsAI, ZhaoRC, ShiY. 2008. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2:141–150.
32.
BouffiC, BonyC, CourtiesG, JorgensenC, NoelD. 2010. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One, 5:e14247.
33.
DjouadF, CharbonnierLM, BouffiC, Louis-PlenceP, BonyC, ApparaillyF, CantosC, JorgensenC, NoelD. 2007. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells, 25:2025–2032.
34.
Lukacs-KornekV, MalhotraD, FletcherAL, ActonSE, ElpekKG, TayaliaP, CollierAR, TurleySJ. 2011. Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nat Immunol, 12:1096–1104.
35.
MatysiakM, OrlowskiW, Fortak-MichalskaM, JurewiczA, SelmajK. 2011. Immunoregulatory function of bone marrow mesenchymal stem cells in EAE depends on their differentiation state and secretion of PGE2. J Neuroimmunol, 233:106–111.
36.
MeiselR, ZibertA, LaryeaM, GobelU, DaubenerW, DillooD. 2004. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103:4619–4621.
37.
MellorAL, MunnDH. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol, 4:762–774.
38.
MougiakakosD, JitschinR, JohanssonCC, OkitaR, KiesslingR, Le BlancK. 2011. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood, 117:4826–4835.
39.
NemethK, LeelahavanichkulA, YuenPS, MayerB, ParmeleeA, DoiK, RobeyPG, LeelahavanichkulK, KollerBHet al.2009. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med, 15:42–49.
40.
RenG, SuJ, ZhangL, ZhaoX, LingW, L'HuillieA, ZhangJ, LuY, RobertsAIet al.2009. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells, 27:1954–1962.
41.
SatoK, OzakiK, OhI, MeguroA, HatanakaK, NagaiT, MuroiK, OzawaK. 2007. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood, 109:228–234.
42.
SelmaniZ, NajiA, ZidiI, FavierB, GaiffeE, ObertL, BorgC, SaasP, TiberghienPet al.2008. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells, 26:212–222.
43.
SpaggiariGM, CapobiancoA, AbdelrazikH, BecchettiF, MingariMC, MorettaL. 2008. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 111:1327–1333.
44.
DelormeB, NivetE, GaillardJ, HäuplT, RingeJ, DevèzeA, MagnanJ, SohierJ, KhrestchatiskyMet al.2010. The human nose harbors a niche of olfactory ectomesenchymal stem cells displaying neurogenic and osteogenic properties. Stem Cells Dev, 19:853–866.
45.
GirardSD, DevezeA, NivetE, GepnerB, RomanFS, FeronF. 2011. Isolating nasal olfactory stem cells from rodents or humans. J Vis Exp, pii:2762.
46.
NivetE, VignesM, GirardSD, PierrisnardC, BarilN, DevèzeA, MagnanJ, LantéF, KhrestchatiskyM, FéronF, RomanFS. 2011. Engraftment of human nasal olfactory stem cells restores neuroplasticity in mice with hippocampal lesions. J Clin Invest, 121:2808–2820.
47.
BifariF, DecimoI, ChiamuleraC, BersanE, MalpeliG, JohanssonJ, LisiV, BonettiB, FumagalliG, PizzoloG, KramperaM. 2009. Novel stem/progenitor cells with neuronal differentiation potential reside in the leptomeningeal niche. J Cell Mol Med, 13:3195–3208.
48.
DecimoI, BifariF, RodriguezFJ, MalpeliG, DolciS, LavariniV, PrettoS, VasquezS, SciancaleporeMet al.2011. Nestin- and doublecortin-positive cells reside in adult spinal cord meninges and participate in injury-induced parenchymal reaction. Stem Cells, 29:2062–2076.
49.
De CoppiP, BartschGJr., SiddiquiMM, XuT, SantosCC, PerinL, MostoslavskyG, SerreAC, SnyderEYet al.2007. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol, 25:100–106.
50.
BearziC, RotaM, HosodaT, TillmannsJ, NascimbeneA, De AngelisA, Yasuzawa-AmanoS, TrofimovaI, SigginsRWet al.2007. Human cardiac stem cells. Proc Natl Acad Sci U S A, 104:14068–14073.
51.
BolliR, ChughAR, D'AmarioD, LoughranJH, StoddardMF, IkramS, BeacheGM, WagnerSG, LeriAet al.2011. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet, 378:1847–1857.
52.
ChughAR, BeacheGM, LoughranJH, MewtonN, ElmoreJB, KajsturaJ, PappasP, TatoolesA, StoddardMFet al.2012. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation, 126:S54–S64.
53.
KajsturaJ, RotaM, HallSR, HosodaT, D'AmarioD, SanadaF, ZhengH, OgorekB, Rondon-ClavoCet al.2011. Evidence for human lung stem cells. N Engl J Med, 364:1795–1806.
54.
RotaC, ImbertiB, PozzobonM, PiccoliM, De CoppiP, AtalaA, GagliardiniE, XinarisC, BenedettiVet al.2012. Human amniotic fluid stem cell preconditioning improves their regenerative potential. Stem Cells Dev, 21:1911–1923.
55.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD, HorwitzE. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
56.
LiuY, WangL, KikuiriT, AkiyamaK, ChenC, XuX, YangR, ChenW, WangS, ShiS. 2011. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat Med, 17:1594–1601.
57.
de HoonMJ, ImotoS, NolanJ, MiyanoS. 2004. Open source clustering software. Bioinformatics, 20:1453–1454.
58.
SaldanhaAJ. 2004. Java Treeview—extensible visualization of microarray data. Bioinformatics, 20:3246–3248.
59.
BrookeG, TongH, LevesqueJP, AtkinsonK. 2008. Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta. Stem Cells Dev, 17:929–940.
60.
De UgarteDA, AlfonsoZ, ZukPA, ElbarbaryA, ZhuM, AshjianP, BenhaimP, HedrickMH, FraserJK. 2003. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett, 89:267–270.
61.
RenG, ZhaoX, ZhangL, ZhangJ, L'HuillierA, LingW, RobertsAI, LeAD, ShiS, ShaoC, ShiY. 2010. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol, 184:2321–2328.
62.
AugelloA, TassoR, NegriniSM, AmateisA, IndiveriF, CanceddaR, PennesiG. 2005. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol, 35:1482–1490.
63.
Luz-CrawfordP, NoelD, FernandezX, KhouryM, FigueroaF, CarrionF, JorgensenC, DjouadF. 2012. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One, 7:e45272.
64.
NajarM, RaicevicG, Fayyad-KazanH, De BruynC, BronD, ToungouzM, LagneauxL. 2012. Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming. Stem Cell Rev, 8:1188–1198.
65.
BottinoC, CastriconiR, MorettaL, MorettaA. 2005. Cellular ligands of activating NK receptors. Trends Immunol, 26:221–226.
66.
PoggiA, PrevostoC, MassaroAM, NegriniS, UrbaniS, PierriI, SaccardiR, GobbiM, ZocchiMR. 2005. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol, 175:6352–6360.
67.
BenvenutoF, FerrariS, GerdoniE, GualandiF, FrassoniF, PistoiaV, MancardiG, UccelliA. 2007. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells, 25:1753–1760.
68.
CaplanAI. 2007. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol, 213:341–347.
69.
EmingSA, KriegT, DavidsonJM. 2007. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol, 127:514–525.
70.
ChenY, XiangLX, ShaoJZ, PanRL, WangYX, DongXJ, ZhangGR. 2010. Recruitment of endogenous bone marrow mesenchymal stem cells towards injured liver. J Cell Mol Med, 14:1494–1508.
71.
SasakiM, AbeR, FujitaY, AndoS, InokumaD, ShimizuH. 2008. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol, 180:2581–2587.
72.
WuY, ChenL, ScottPG, TredgetEE. 2007. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells, 25:2648–2659.
73.
AnversaP, KajsturaJ, RotaM, LeriA. 2013. Regenerating new heart with stem cells. J Clin Invest, 123:62–70.
74.
AnversaP, PerrellaMA, KourembanasS, ChoiAM, LoscalzoJ. 2012. Regenerative pulmonary medicine: potential and promise, pitfalls and challenges. Eur J Clin Invest, 42:900–913.
75.
BearziC, LeriA, Lo MonacoF, RotaM, GonzalezA, HosodaT, PepeM, QanudK, OjaimiCet al.2009. Identification of a coronary vascular progenitor cell in the human heart. Proc Natl Acad Sci U S A, 106:15885–15890.
76.
UrbanekK, CesselliD, RotaM, NascimbeneA, De AngelisA, HosodaT, BearziC, BoniA, BolliRet al.2006. Stem cell niches in the adult mouse heart. Proc Natl Acad Sci U S A, 103:9226–9231.
77.
HosodaT, D'AmarioD, Cabral-Da-SilvaMC, ZhengH, Padin-IruegasME, OgorekB, Ferreira-MartinsJ, Yasuzawa-AmanoS, AmanoKet al.2009. Clonality of mouse and human cardiomyogenesis in vivo. Proc Natl Acad Sci U S A, 106:17169–17174.
78.
KramperaM, GalipeauJ, ShiY, TarteK, Sensebe;L. and On behalf of the MSC Committee of the International Society for Cellular Therapy ISCT. 2013. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy, pii:S1465–3249(13)00411-8.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
